The genomic landscape of prostate cancer.

Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23

HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene (2015) 1.45

Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol (2013) 1.17

RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov (2014) 0.93

Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy. Int J Mol Sci (2015) 0.82

Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome. Methods (2015) 0.79

Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups. PLoS One (2014) 0.79

Concurrent Down-Regulation of PTEN and NKX3.1 Expression in Iranian Patients with Prostate Cancer. Int Braz J Urol (2015) 0.75

Deletion of 18q is a strong and independent prognostic feature in prostate cancer. Oncotarget (2016) 0.75

Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. Genome Biol (2017) 0.75

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56

An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06

Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41

Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09

A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27

Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83

A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39

Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83

The genomic complexity of primary human prostate cancer. Nature (2011) 14.06

Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94

Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93

Active genes dynamically colocalize to shared sites of ongoing transcription. Nat Genet (2004) 9.57

Frequent mutation of BAP1 in metastasizing uveal melanomas. Science (2010) 7.47

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61

Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08

Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet (2001) 5.92

Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (2007) 5.79

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81

Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71

Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59

Roles for Nkx3.1 in prostate development and cancer. Genes Dev (1999) 4.30

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res (2005) 3.98

Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res (1995) 3.98

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83

Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53

Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37

Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29

Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res (1999) 3.29

Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res (2007) 3.13

The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09

Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A (2002) 2.89

A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89

Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res (1999) 2.88

Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res (1997) 2.80

Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A (2000) 2.65

Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res (2007) 2.60

A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48

BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer (2006) 2.45

Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res (2000) 2.44

Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res (2010) 2.41

Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40

Beta-catenin mutations in human prostate cancer. Cancer Res (1998) 2.37

PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol (2009) 2.13

Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer (1998) 2.06

FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03

Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02

Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res (1995) 1.85

Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A (2006) 1.78

Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res (1996) 1.78

Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell (2011) 1.74

Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis (2005) 1.70

Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst (1999) 1.70

Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res (2005) 1.66

Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol (2010) 1.61

p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res (1993) 1.59

Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res (1994) 1.59

Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res (2005) 1.57

Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res (2003) 1.55

Mutations in the AXIN1 gene in advanced prostate cancer. Eur Urol (2008) 1.53

Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res (1995) 1.52

The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res (2004) 1.51

Molecular signaling pathways that regulate prostate gland development. Differentiation (2008) 1.47

Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A (2011) 1.47

p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol (1999) 1.46

Detection and analysis of beta-catenin mutations in prostate cancer. Prostate (2000) 1.43

Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res (2009) 1.42

Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.40

Defects of DNA mismatch repair in human prostate cancer. Cancer Res (2001) 1.38

Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene (2005) 1.33

Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res (1995) 1.22

Identification of genetic markers for prostatic cancer progression. Lab Invest (2000) 1.19

Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol (2005) 1.12

A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene (2011) 1.10

Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer (1999) 1.10

Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res (2009) 1.09

Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer (2001) 1.07

Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol (2000) 1.05

Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene (2008) 1.03

Chromosomal clues to the development of prostate tumors. Prostate (1999) 1.03

Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br J Urol (1994) 1.02

NKX3.1 activates cellular response to DNA damage. Cancer Res (2010) 1.01

Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch (2004) 1.00

Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol (1995) 0.99

Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma. J Urol (1994) 0.95

PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Mod Pathol (2010) 0.94

Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol (1995) 0.92

HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci U S A (2011) 0.92

The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83

Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28

BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14

The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88

Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62

The genomic complexity of primary human prostate cancer. Nature (2011) 14.06

High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68

A landscape of driver mutations in melanoma. Cell (2012) 12.61

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93

Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46

Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03

Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77

Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76

Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60

Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96

MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10

Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95

Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07

Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71

An integrated approach to uncover drivers of cancer. Cell (2010) 4.53

Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24

Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43

Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol (2006) 3.39

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38

The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature (2011) 3.37

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13

Clinical implications of the cancer genome. J Clin Oncol (2010) 3.11

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79

Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biol (2009) 2.65

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61

Melanoma: from mutations to medicine. Genes Dev (2012) 2.59

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov (2012) 2.47

Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res (2007) 2.45

An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell (2013) 2.30

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29

Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med (2014) 2.09

An oncogenic role for ETV1 in melanoma. Cancer Res (2010) 1.94

Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell (2010) 1.86

ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res (2012) 1.86

Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol (2014) 1.84

Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet (2013) 1.77

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72

Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther (2010) 1.62

Major copy proportion analysis of tumor samples using SNP arrays. BMC Bioinformatics (2008) 1.62

p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. Mol Cell Biol (2009) 1.36

AKT signaling in physiology and disease. Curr Top Microbiol Immunol (2010) 1.35

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood (2011) 1.28

Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res (2009) 1.21

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs (2013) 1.19

A 2-Mb critical region implicated in the microcephaly associated with terminal 1q deletion syndrome. Am J Med Genet A (2007) 1.16

MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Sci Signal (2012) 1.13

Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn (2011) 1.11

Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov (2013) 1.09

Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res (2006) 1.07

Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A (2014) 1.01

Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Mol Cancer Res (2014) 0.99

Epigenomic alterations in localized and advanced prostate cancer. Neoplasia (2013) 0.96

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep (2016) 0.96

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med (2014) 0.95

C-RAF mutations confer resistance to RAF inhibitors. Cancer Res (2013) 0.91

Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One (2013) 0.88

Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am (2009) 0.87

PTR1-dependent synthesis of tetrahydrobiopterin contributes to oxidant susceptibility in the trypanosomatid protozoan parasite Leishmania major. Curr Genet (2009) 0.87

Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr Blood Cancer (2012) 0.87

High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest Ophthalmol Vis Sci (2012) 0.82

Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. J Invest Dermatol (2011) 0.81

A Notch for noncoding RNA in melanoma. N Engl J Med (2014) 0.78

Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. Am J Hum Genet (2016) 0.77

Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Mol Cancer Ther (2012) 0.77

Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones. Cell Res (2012) 0.77

Concordance and discordance in tumor genomic profiling. J Clin Oncol (2012) 0.76

Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes. Cancer Cell (2013) 0.75

Stepping on the GAS: a brake pedal for melanoma metastasis? Pigment Cell Melanoma Res (2009) 0.75

Believe the miracles: of biomedical science and human suffering. J Clin Invest (2016) 0.75

Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453-456. J Pathol (2013) 0.75

Integrative Clinical Genomics of Advanced Prostate Cancer. Cell (2015) 0.75